TP53 and cancer: Basically, this model implies that PDAC development is dictated by the progressive acquisition of genetic alterations (KRAS, followed by CDKN2A, then TP53 and SMAD4), with a gradual evolutionary trajectory of cancer progression because each alteration is acquired independently.